NEW YORK – Color and Verily said today that they are collaborating to return actionable genetic information to participants in the Project Baseline Health Study, a four-year observational study that aims to precisely define the baseline of good health and study the transition to disease.
Participants in the study, which is led by Verily, will receive access to Color's physician-ordered genomic services, board certified genetic counselors, and clinical pharmacists in order to better understand their risk for certain hereditary cancers, heart disease, and any pharmacogenomic variants they might have, the companies said. The initiative will support Project Baseline's efforts to engage people in contributing to the study of human health and participate in clinical research.
They also noted that they aim to showcase a new delivery model for efficient and cost-effective return of actionable results. Study participants will be able to work with their physicians to integrate their results into their healthcare, including preventive actions plans if they are at a higher risk of a hereditary condition covered by Color's tests.